{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T17:54:43Z","timestamp":1758477283019,"version":"3.37.3"},"reference-count":38,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1124\/jpet.116.232942","type":"journal-article","created":{"date-parts":[[2016,3,31]],"date-time":"2016-03-31T02:07:03Z","timestamp":1459390023000},"page":"495-508","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["TASP0434299: A Novel Pyridopyrimidin-4-One Derivative as a Radioligand for Vasopressin V1B Receptor"],"prefix":"10.1016","volume":"357","author":[{"given":"Kazumi","family":"Koga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsukane","family":"Yoshinaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshikatsu","family":"Uematsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Miyakoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Shimoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Fujinaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takafumi","family":"Minamimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Rong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Higuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norikazu","family":"Ohtake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Suhara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeyuki","family":"Chaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.116.232942_bib1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0167-0115(00)00196-8","article-title":"Vasopressinergic regulation of the hypothalamic-pituitary-adrenal axis: implications for stress adaptation","volume":"96","author":"Aguilera","year":"2000","journal-title":"Regul Pept"},{"key":"10.1124\/jpet.116.232942_bib2","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.tips.2015.03.002","article-title":"Amyloid biomarkers in Alzheimer\u2019s disease","volume":"36","author":"Blennow","year":"2015","journal-title":"Trends Pharmacol Sci"},{"key":"10.1124\/jpet.116.232942_bib3","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/jpet.116.232942_bib4","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1172\/JCI118547","article-title":"The pituitary V3 vasopressin receptor and the corticotroph phenotype in ectopic ACTH syndrome","volume":"97","author":"de Keyzer","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1124\/jpet.116.232942_bib5","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1677\/joe.0.1290197","article-title":"An autoradiographical study of binding sites for vasopressin located on corticotrophs in rat and sheep pituitary glands","volume":"129","author":"Du Pasquier","year":"1991","journal-title":"J Endocrinol"},{"key":"10.1124\/jpet.116.232942_bib6","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1365-2826.1991.tb00277.x","article-title":"Neurophysins, rather than receptors, are Involved in [3H]oxytocin and [3H]vasopressin binding detected by autoradiography in the hypothalamo-neurohypophyseal system","volume":"3","author":"Freund-Mercier","year":"1991","journal-title":"J Neuroendocrinol"},{"key":"10.1124\/jpet.116.232942_bib7","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.4088\/JCP.12m07804","article-title":"The vasopressin V1b receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies","volume":"73","author":"Griebel","year":"2012","journal-title":"J Clin Psychiatry"},{"key":"10.1124\/jpet.116.232942_bib8","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/sj.bjp.0706383","article-title":"Selectivity of d[Cha4]AVP and SSR149415 at human vasopressin and oxytocin receptors: evidence that SSR149415 is a mixed vasopressin V1b\/oxytocin receptor antagonist","volume":"146","author":"Griffante","year":"2005","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.116.232942_bib9","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/j.0953-8194.2004.01163.x","article-title":"The discovery of novel vasopressin V1b receptor ligands for pharmacological, functional and structural investigations","volume":"16","author":"Guillon","year":"2004","journal-title":"J Neuroendocrinol"},{"key":"10.1124\/jpet.116.232942_bib10","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.nbd.2013.08.017","article-title":"Translational PET imaging research","volume":"61","author":"Hargreaves","year":"2014","journal-title":"Neurobiol Dis"},{"key":"10.1124\/jpet.116.232942_bib11","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1210\/endo.142.4.8067","article-title":"Immunohistochemical localization of the vasopressin V1b receptor in the rat brain and pituitary gland: anatomical support for its involvement in the central effects of vasopressin","volume":"142","author":"Hernando","year":"2001","journal-title":"Endocrinology"},{"key":"10.1124\/jpet.116.232942_bib12","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1111\/bph.12699","article-title":"Antidepressant and anxiolytic profiles of newly synthesized arginine vasopressin V1B receptor antagonists: TASP0233278 and TASP0390325","volume":"171","author":"Iijima","year":"2014","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.116.232942_bib13","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00213-015-4089-5","article-title":"Clinical safety and hypothalamic-pituitary-adrenal axis effects of the arginine vasopressin type 1B receptor antagonist ABT-436","volume":"233","author":"Katz","year":"2016","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.116.232942_bib14","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/356526a0","article-title":"Structure and expression of a human oxytocin receptor","volume":"356","author":"Kimura","year":"1992","journal-title":"Nature"},{"key":"10.1124\/jpet.116.232942_bib15","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13550-016-0170-2","article-title":"Development of TASP0410457 (TASP457), a novel dihydroquinolinone derivative as a PET radioligand for central histamine H3 receptors","volume":"6","author":"Koga","year":"2016","journal-title":"EJNMMI Res"},{"key":"10.1124\/jpet.116.232942_bib16","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1152\/physrev.00035.2011","article-title":"Vasopressin V1a and V1b receptors: from molecules to physiological systems","volume":"92","author":"Koshimizu","year":"2012","journal-title":"Physiol Rev"},{"key":"10.1124\/jpet.116.232942_bib17","doi-asserted-by":"crossref","first-page":"6783","DOI":"10.1073\/pnas.92.15.6783","article-title":"Extrapituitary expression of the rat V1b vasopressin receptor gene","volume":"92","author":"Lolait","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.116.232942_bib18","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/357336a0","article-title":"Cloning and characterization of a vasopressin V2 receptor and possible link to nephrogenic diabetes insipidus","volume":"357","author":"Lolait","year":"1992","journal-title":"Nature"},{"key":"10.1124\/jpet.116.232942_bib19","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/j.1365-2826.2012.02303.x","article-title":"Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics","volume":"24","author":"Manning","year":"2012","journal-title":"J Neuroendocrinol"},{"key":"10.1124\/jpet.116.232942_bib20","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0079-6123(08)00437-8","article-title":"Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents","volume":"170","author":"Manning","year":"2008","journal-title":"Prog Brain Res"},{"key":"10.1124\/jpet.116.232942_bib21","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.neuron.2013.07.037","article-title":"Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls","volume":"79","author":"Maruyama","year":"2013","journal-title":"Neuron"},{"key":"10.1124\/jpet.116.232942_bib22","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1124\/dmd.105.006213","article-title":"In vitro and in vivo evaluation of the metabolism and bioavailability of ester prodrugs of mgs0039 (3-(3,4-dichlorobenzyloxy)-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid), a potent metabotropic glutamate receptor antagonist","volume":"34","author":"Nakamura","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.116.232942_bib23","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1124\/mol.65.3.623","article-title":"Vasopressin stimulates insulin release from islet cells through V1b receptors: a combined pharmacological\/knockout approach","volume":"65","author":"Oshikawa","year":"2004","journal-title":"Mol Pharmacol"},{"key":"10.1124\/jpet.116.232942_bib24","doi-asserted-by":"crossref","first-page":"5189","DOI":"10.1210\/endo.138.12.5580","article-title":"Regulation of pituitary V1b vasopressin receptor messenger ribonucleic acid by adrenalectomy and glucocorticoid administration","volume":"138","author":"Rabadan-Diehl","year":"1997","journal-title":"Endocrinology"},{"key":"10.1124\/jpet.116.232942_bib25","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0378-1119(99)00468-0","article-title":"Nucleotide sequence and structural organization of the human vasopressin pituitary receptor (V3) gene","volume":"241","author":"Ren\u00e9","year":"2000","journal-title":"Gene"},{"key":"10.1124\/jpet.116.232942_bib26","doi-asserted-by":"crossref","unstructured":"Roper J (2011) The Vasopressin Avpr1b Receptor: Molecular and Pharmacological Studies, Doctoral thesis, Bristol University, Bristol, U.K.","DOI":"10.3109\/10253890.2010.512376"},{"key":"10.1124\/jpet.116.232942_bib27","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1006\/bbrc.1995.2033","article-title":"Molecular cloning and characterization of rat V1b vasopressin receptor: evidence for its expression in extra-pituitary tissues","volume":"212","author":"Saito","year":"1995","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/jpet.116.232942_bib28","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.1016\/j.bmcl.2010.03.108","article-title":"Synthesis of [11C]SSR149415 and preliminary imaging studies using positron emission tomography","volume":"20","author":"Sch\u00f6nberger","year":"2010","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1124\/jpet.116.232942_bib29","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1016\/S0024-3205(98)00027-7","article-title":"Vasopressin and the regulation of hypothalamic-pituitary-adrenal axis function: implications for the pathophysiology of depression","volume":"62","author":"Scott","year":"1998","journal-title":"Life Sci"},{"key":"10.1124\/jpet.116.232942_bib30","doi-asserted-by":"crossref","first-page":"R938","DOI":"10.1152\/ajpregu.00062.2007","article-title":"Biological characterization of rodent and human vasopressin V1b receptors using SSR-149415, a nonpeptide V1b receptor ligand","volume":"293","author":"Serradeil-Le Gal","year":"2007","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1124\/jpet.116.232942_bib31","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1124\/jpet.300.3.1122","article-title":"Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist","volume":"300","author":"Serradeil-Le Gal","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.116.232942_bib32","doi-asserted-by":"crossref","first-page":"27088","DOI":"10.1016\/S0021-9258(18)47129-3","article-title":"Molecular cloning and functional expression of a cDNA encoding the human V1b vasopressin receptor","volume":"269","author":"Sugimoto","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.116.232942_bib38","first-page":"285","article-title":"Guidelines for animal experimentation","volume":"36","year":"1987","journal-title":"Exp Anim"},{"key":"10.1124\/jpet.116.232942_bib33","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.1016\/S0021-9258(17)41863-1","article-title":"Molecular cloning, sequencing, and functional expression of a cDNA encoding the human V1a vasopressin receptor","volume":"269","author":"Thibonnier","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.116.232942_bib34","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0006-8993(88)91437-0","article-title":"Localization and pharmacological characterization of high affinity binding sites for vasopressin and oxytocin in the rat brain by light microscopic autoradiography","volume":"442","author":"Tribollet","year":"1988","journal-title":"Brain Res"},{"key":"10.1124\/jpet.116.232942_bib35","doi-asserted-by":"crossref","first-page":"5015","DOI":"10.1210\/endo.139.12.6382","article-title":"Comparative distribution of vasopressin V1b and oxytocin receptor messenger ribonucleic acids in brain","volume":"139","author":"Vaccari","year":"1998","journal-title":"Endocrinology"},{"key":"10.1124\/jpet.116.232942_bib36","unstructured":"Yoshinaga M, Miyakoshi N and Koga K (2013), inventors, Taisho Pharmaceutical Co. Ltd., assignee. Pyridopyrimidin-4-one derivative. International Application No. PCT\/JP2013\/066950."},{"key":"10.1124\/jpet.116.232942_bib37","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.neuroscience.2006.08.040","article-title":"The vasopressin 1b receptor is prominent in the hippocampal area CA2 where it is unaffected by restraint stress or adrenalectomy","volume":"143","author":"Young","year":"2006","journal-title":"Neuroscience"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524193238?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524193238?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.116.232942","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T19:45:20Z","timestamp":1739994320000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524193238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S0022356524193238"],"URL":"https:\/\/doi.org\/10.1124\/jpet.116.232942","relation":{},"ISSN":["0022-3565"],"issn-type":[{"type":"print","value":"0022-3565"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TASP0434299: A Novel Pyridopyrimidin-4-One Derivative as a Radioligand for Vasopressin V1B Receptor","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.116.232942","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}